Umbelliferone β-d-galactopyranoside inhibits chemically induced renal carcinogenesis via alteration of oxidative stress, hyperproliferation and inflammation: possible role of NF-κB

Paederia foetida Linn. inhibits adjuvant induced arthritis by suppression of PGE2 and COX-2 expression via nuclear factor-κB

(2015) Vikas Kumar et al.   Food & Function

In vivoantinociceptive and anti-inflammatory activities of umbelliferone isolated fromPotentilla evestita

(2014) Abdur Rauf et al.   NATURAL PRODUCT RESEARCH

Umbelliferone β-D-galactopyranoside from Aegle marmelos (L.) corr. an ethnomedicinal plant with antidiabetic, antihyperlipidemic and antioxidative activity

(2013) Vikas Kumar et al.   BMC Complementary and Alternative Medicine

Characterization of N-diethylnitrosamine-initiated and ferric nitrilotriacetate-promoted renal cell carcinoma experimental model and effect of a tamarind seed extract against acute nephrotoxicity and carcinogenesis

(2012) Chabetty Y. Vargas-Olvera et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: Plausible role of NF-κB

(2012) Muneeb U. Rehman et al.   TOXICOLOGY LETTERS

Prostaglandins and Inflammation

(2011) Emanuela Ricciotti et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The emerging role of nuclear factor kappa B in renal cell carcinoma

(2011) Christudas Morais et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Thymoquinone Attenuates Diethylnitrosamine Induction of Hepatic Carcinogenesis Through Antioxidant Signaling

(2010) Mohamed M. Sayed-Ahmed et al.   Oxidative Medicine and Cellular Longevity

Effects of umbelliferone in a murine model of allergic airway inflammation

(2009) Juliana F. Vasconcelos et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review

(2008) Kiran Gupta et al.   CANCER TREATMENT REVIEWS

NF-κB in carcinoma therapy and prevention

(2008) Matthew Brown et al.   EXPERT OPINION ON THERAPEUTIC TARGETS